These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 17961161

  • 1. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
    [Abstract] [Full Text] [Related]

  • 2. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [Abstract] [Full Text] [Related]

  • 3. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [Abstract] [Full Text] [Related]

  • 4. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, Szczylik C, Jakobsen A.
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [Abstract] [Full Text] [Related]

  • 5. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC.
    Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
    [Abstract] [Full Text] [Related]

  • 6. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 7. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD, Waldstrøm M, Jakobsen A.
    Int J Gynecol Cancer; 2009 Jul 20; 19(5):820-5. PubMed ID: 19574766
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, Krivak TC, Niedernhofer LJ.
    Gynecol Oncol; 2012 Sep 20; 126(3):448-54. PubMed ID: 22609620
    [Abstract] [Full Text] [Related]

  • 9. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhao D, Zhang W, Li XG, Wang XB, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.
    Zhonghua Zhong Liu Za Zhi; 2012 Mar 20; 34(3):196-200. PubMed ID: 22780973
    [Abstract] [Full Text] [Related]

  • 10. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis.
    Li Y, Hu P, Cao Y, Wang GY, Wang N, Zhou RM.
    Biomarkers; 2014 Mar 20; 19(2):128-34. PubMed ID: 24499239
    [Abstract] [Full Text] [Related]

  • 11. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R.
    Anticancer Res; 2014 Jan 20; 34(1):393-9. PubMed ID: 24403493
    [Abstract] [Full Text] [Related]

  • 12. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial.
    J Clin Oncol; 2008 Jul 20; 26(21):3598-606. PubMed ID: 18640939
    [Abstract] [Full Text] [Related]

  • 13. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren T, Ge RL.
    J Cancer Res Ther; 2013 Jul 20; 9(3):410-5. PubMed ID: 24125975
    [Abstract] [Full Text] [Related]

  • 14. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
    Liblab S, Vusuratana A, Areepium N.
    Asian Pac J Cancer Prev; 2020 Jul 01; 21(7):1925-1929. PubMed ID: 32711417
    [Abstract] [Full Text] [Related]

  • 15. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N.
    J Thorac Oncol; 2007 Oct 01; 2(10):902-6. PubMed ID: 17909351
    [Abstract] [Full Text] [Related]

  • 16. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
    Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB, Deloia JA.
    Gynecol Oncol; 2011 Jul 01; 122(1):121-6. PubMed ID: 21496891
    [Abstract] [Full Text] [Related]

  • 17. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 18. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
    Bogush TA, Popova AS, Dudko EA, Bogush EA, Tyulyandina AS, Tyulyandin SA, Davydov MI.
    Antibiot Khimioter; 2015 Jun 01; 60(3-4):42-50. PubMed ID: 26415382
    [Abstract] [Full Text] [Related]

  • 19. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 01; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 20. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
    Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP.
    Exp Mol Med; 2006 Jun 30; 38(3):320-4. PubMed ID: 16819291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.